Comparative Pharmacology
Head-to-head clinical analysis: PHOSPHOTOPE versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSPHOTOPE versus SODIUM IODIDE I 123.
PHOSPHOTOPE vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical